Curian Capital’s Novo Nordisk NVO Stock Holding History

Curian Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-63,078	Closed	-$1.83M	–	264
2015 Q4	$1.83M	Sell	63,078 -112,866	-64%	-$3.12M	0.14%	160
2015 Q3	$4.77M	Sell	175,944 -34,978	-17%	-$990K	0.13%	185
2015 Q2	$5.78M	Buy	+210,922	New	+$5.93M	0.1%	231
2013 Q4	–	Sell	-360,040	Closed	-$6.09M	–	566
2013 Q3	$6.09M	Sell	360,040 -4,630	-1%	-$77.9K	0.11%	187
2013 Q2	$5.65M	Buy	+364,670	New	+$6.07M	0.1%	186

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Curian Capital's NVO Position: Q1 2016 in Review

Curian Capital sold out of Novo Nordisk (NVO) in Q1 2016, closing a stake of 63,078 shares — an estimated $1.83M sold.

Curian Capital first reported a position in NVO in Q2 2013 and held it in 5 quarters. The position peaked at $6.09M in Q3 2013. 535 funds tracked by Wall St. Rank hold NVO as of Q1 2016.

Curian Capital reported no remaining Novo Nordisk position as of Q1 2016 after selling out during the quarter.
Curian Capital sold 63,078 Novo Nordisk shares in Q1 2016, an estimated $1.83M.
Curian Capital first reported a position in Novo Nordisk in Q2 2013 and held it in 5 quarters.
Curian Capital's Novo Nordisk position peaked at $6.09M in Q3 2013.
535 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2016.

Based on Curian Capital's 13F filing for Q1 2016.